OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Clinical development and potential of photothermal and photodynamic therapies for cancer	1697
Broadening horizons: the role of ferroptosis in cancer	1267
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	839
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors	709
Immunotherapies for hepatocellular carcinoma	685
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	675
Liquid biopsy enters the clinic — implementation issues and future challenges	617
Exploring the NK cell platform for cancer immunotherapy	613
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities	596
Unlocking the potential of antibody–drug conjugates for cancer therapy	523
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	496
Clinical and therapeutic relevance of cancer-associated fibroblasts	458
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	447
TGFβ biology in cancer progression and immunotherapy	425
The emerging roles of circRNAs in cancer and oncology	413
Immune-checkpoint inhibitors: long-term implications of toxicity	387
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	370
Advancing therapy for osteosarcoma	339
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	324
Harnessing cytokines and chemokines for cancer therapy	324
Rising incidence of early-onset colorectal cancer — a call to action	280
Clinical relevance of tumour-associated macrophages	276
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	273
The adenosine pathway in immuno-oncology	269
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	264

Predicting cancer outcomes with radiomics and artificial intelligence in radiology	244
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives	225
Nasopharyngeal carcinoma: an evolving paradigm	219
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	213
Targeting drugs to tumours using cell membrane-coated nanoparticles	212
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper	211
Understanding and overcoming resistance to PARP inhibitors in cancer therapy	209
Clinical implications of T cell exhaustion for cancer immunotherapy	208
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	197
Therapeutic targeting of the hypoxic tumour microenvironment	195
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	178
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	176
Personalized early detection and prevention of breast cancer: ENVISION consensus statement	174
Artificial intelligence in radiation oncology	173
Senescence and cancer — role and therapeutic opportunities	172
Tumour budding in solid cancers	169
Long-term outcomes following CAR T cell therapy: what we know so far	169
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	167
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	163
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	163
MET-dependent solid tumours — molecular diagnosis and targeted therapy	162
The implications of IDH mutations for cancer development and therapy	158
CAR T cell therapies for patients with multiple myeloma	157
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	150
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	149
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	145
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	144
The current state of the art and future trends in RAS-targeted cancer therapies	144
Towards precision medicine for AML	142
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	141
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	139
Immunogenicity of CAR T cells in cancer therapy	135
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	135
Fundamentals and developments in fluorescence-guided cancer surgery	131
The emerging role of photoacoustic imaging in clinical oncology	130
ROS1-dependent cancers — biology, diagnostics and therapeutics	128
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire	124
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	119
Protein degraders enter the clinic — a new approach to cancer therapy	119
The blood–tumour barrier in cancer biology and therapy	118
Tumour burden and efficacy of immune-checkpoint inhibitors	118
The nuclear export protein XPO1 — from biology to targeted therapy	116
Precision oncology in metastatic colorectal cancer — from biology to medicine	114
Integrating evolutionary dynamics into cancer therapy	110
Advancing therapy for neuroblastoma	106
Radiotheranostics in oncology: current challenges and emerging opportunities	103
Circulating tumour DNA — looking beyond the blood	102
Therapy with oncolytic viruses: progress and challenges	101
Novel approaches to target the microenvironment of bone metastasis	99
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	99

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	98
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	95
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours	95
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice	95
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	92
The global burden of lung cancer: current status and future trends	88
The emerging roles of γδ T cells in cancer immunotherapy	88
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	83